Erythropoiesis-stimulating agents can be used to treat anemia; however, it is unknown whether these agents improve prognosis, and experimental studies indicate that erythropoietin may induce the expression of the vascular endothelial growth factor and stimulate tumor recurrence in mice. Here, VEGFA is linked to neoplasm.